Method for separating, identifying and quantifying ibrutinib Z3 and genotoxic impurities thereof
Through liquid chromatography-mass spectrometry combined technology and gradient elution program, idrutinib Z3 and its seven genotoxic impurities were successfully isolated and identified, solving the problem that the existing technology could not be effectively detected, and achieving high sensitivity and accuracy quality control.
Patent Information
- Application Number
- CN202411331018.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-23
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art cannot effectively isolate and detect idrutinib Z3 and its seven genotoxic impurities, making it difficult to meet the limit requirements of quality control.
Ibratinib Z3 was isolated and identified using liquid chromatography-mass spectrometry combined with gradient elution program using octadecyl-bonded silica gel chromatography column and mobile phase of formic acid aqueous solution and organic solvent. Its seven genotoxic impurities are multi-reaction detection through a tandem quadrupole mass spectrometer to achieve qualitative and quantitative analysis.
Effectively separate ibrutinib Z3 and its seven impurities within 25 minutes, improving the sensitivity and accuracy of detection, meeting limit requirements, and being able to detect impurities of about 0.94 ng/ml, with high specialization and reproduction sex.
Smart Images

Figure CN118914411A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of drug analysis, and in particular relates to a separation, identification and quantification method of ibrutinib Z3 and its genotoxic impurities. Background Art
[0002] Ibrutinib is a highly effective and selective small molecule Bruton's tyrosine kinase (BTK) inhibitor that specifically inhibits the activity of BTK, thereby inhibiting the proliferation and survival of malignant B cells in vivo, as well as cell migration and substrate adhesion in vitro, thereby exerting its anti-cancer effect. As the world's first BTK inhibitor, ibrutinib has brought breakthrough progress in the efficacy of a variety of B-cell malignancies, including mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL) and Waldenstrom's macroglobulinemia (WM).
[0003] Ibrutinib Z3, whose structural formula is shown in Formula I, is a key intermediate in the synthesis of Ibrutinib. Studies have shown that the impurity Z may be introduced into Ibrutinib Z3 during the synthesis process. 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e There are 7 impurities in total, impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The structural formulas are shown in Formula II to Formula VIII. The seven impurities are all genotoxic impurities with warning structures, and the limit requirement is 23.5 ppm, but the sensitivity of conventional LC or GC methods cannot meet the requirement.
[0004]
[0005] Some technicians have analyzed the impurities that appear in the preparation process of ibrutinib. For example, patent CN106153797A discloses a method for analyzing related substances of ibrutinib and ibrutinib preparations, which uses octadecylsilane bonded silica gel or octylsilane bonded silica gel as a chromatographic column filler, and a combination of a buffer solution and an organic solvent as a mobile phase to perform qualitative and quantitative analysis on ibrutinib and related substances of ibrutinib preparations. Patent CN104407067A discloses a liquid phase separation and detection method for ibrutinib and its enantiomeric impurities, and the chromatographic conditions include: using AD-H, 4.6mmX250mm, 5μm, a chiral chromatographic column as a separation chromatographic column; using a mixed solvent of an alkane solvent and an alcohol solvent as the mobile phase, and the volume ratio of the alkane solvent to the alcohol solvent is 35:65. However, these patents cannot effectively separate and detect the above-mentioned 7 genotoxic impurities.
[0006] The existing technology lacks a method that can effectively determine the genotoxic impurities of ibrutinib Z3 and its seven genotoxic impurities. Therefore, it is necessary to develop a convenient, fast, precise and accurate detection method for the detection of impurity Z in ibrutinib Z3. 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e control. Summary of the invention
[0007] In view of this, one of the objects of the present invention is to provide a method for separating ibrutinib Z3 and its genotoxic impurities, which can effectively separate ibrutinib Z3 and its seven genotoxic impurities within 25 minutes or more, providing support for subsequent qualitative and quantitative analysis of each impurity.
[0008] To achieve the above object, the present invention adopts the following technical solutions:
[0009] A method for separating ibrutinib Z3 and its genotoxic impurities, wherein ibrutinib Z3 and its genotoxic impurities are separated by LC-MS / MS; the chromatographic column of the LC-MS / MS method uses octadecyl bonded silica gel as a filler, and the mobile phase includes a mobile phase A and a mobile phase B, wherein the mobile phase A is a formic acid aqueous solution, and the mobile phase B is an organic solvent; ibrutinib Z3 and its genotoxic impurities are separated by gradient elution;
[0010] The genotoxic impurities include impurity Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z2c 、Impurity Z 2d 、Impurity Z 2e Any one or more of; the structural formula of Ibrutinib Z3 is as shown in Formula I, the impurity Z 1b The structural formula is shown in Formula II, and the impurity Z 1f The structural formula is shown in Formula III, and the impurity Z 2a The structural formula is shown in Formula IV, and the impurity Z 2b The structural formula of is shown in Formula V, the impurity Z 2c The structural formula of is shown in Formula VI, the impurity Z 2d The structural formula of is shown in Formula VII, the impurity Z 2e The structural formula is shown in Formula VIII;
[0011]
[0012]
[0013] Preferably, the concentration of the formic acid aqueous solution is 0.1% to 0.3%, and the organic solvent is acetonitrile. Most preferably, the concentration of the formic acid aqueous solution is 0.2%.
[0014] Further, the following elution program was used for gradient elution:
[0015] 0min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25;
[0016] 5min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25;
[0017] 10 min, the volume ratio of the mobile phase A to the mobile phase B is 10-30:90-70;
[0018] 15min, the volume ratio of the mobile phase A to the mobile phase B is 10-30:90-70;
[0019] 15.1min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25;
[0020] 25min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25.
[0021] Preferably, the following elution program is used for gradient elution: 0 min, the volume ratio of the mobile phase A to the mobile phase B is 63-67:37-33;
[0022] 5min, the volume ratio of the mobile phase A to the mobile phase B is 63-67:37-33;
[0023] 10 min, the volume ratio of the mobile phase A to the mobile phase B is 18-22:82-78;
[0024] 15min, the volume ratio of the mobile phase A to the mobile phase B is 18-22:82-78;
[0025] 15.1min, the volume ratio of the mobile phase A to the mobile phase B is 63-67:37-33;
[0026] 25min, the volume ratio of the mobile phase A to the mobile phase B is 63-67:37-33.
[0027] As the most preferred, the gradient elution is performed using the following elution program:
[0028] 0min, the volume ratio of the mobile phase A to the mobile phase B is 65:35;
[0029] 5 min, the volume ratio of the mobile phase A to the mobile phase B is 65:35;
[0030] 10 min, the volume ratio of the mobile phase A to the mobile phase B is 20:80;
[0031] 15 min, the volume ratio of the mobile phase A to the mobile phase B is 20:80;
[0032] 15.1min, the volume ratio of the mobile phase A to the mobile phase B is 65:35;
[0033] 25min, the volume ratio of the mobile phase A to the mobile phase B is 65:35.
[0034] Furthermore, the flow rate was set to 1.0±0.2 ml / min, the column temperature was set to 30±2°C, and the injector temperature was controlled to 6±1°C.
[0035] Preferably, the flow rate is set to 0.9 ml / min to 1.1 ml / min.
[0036] As the most preferred method, the flow rate is set to 1 ml / min, the column temperature is set to 30°C, and the injector temperature is controlled to 6°C.
[0037] Preferably, the specifications of the chromatographic column are 4.6 mm×250 mm, 5 μm.
[0038] Most preferably, the chromatographic column is Shim-Pack VP-ODS 4.6 mm×250 mm, 5 μm.
[0039] Preferably, the injection volume is 50 μl.
[0040] Preferably, the running time is 25 minutes.
[0041] The second object of the present invention is to provide a method for identifying ibrutinib Z3 and its genotoxic impurities, which can qualitatively identify a variety of genotoxic impurities in ibrutinib Z3 with a content as low as about 0.9 ng / ml, with a low detection limit and high sensitivity.
[0042] To achieve the above object, the present invention adopts the following technical solutions:
[0043] The method for identifying Ibrutinib Z3 and its genotoxic impurities comprises the following steps:
[0044] (1) separating ibrutinib Z3 and its genotoxic impurities using the aforementioned separation method;
[0045] (2) using a tandem quadrupole mass spectrometer to detect and obtain a chromatogram; the detection mode is multiple reaction detection in the positive ion mode of an electrospray ion source;
[0046] (3) Analyze the chromatographic behavior of the test sample and the reference sample to determine whether the test sample contains the genotoxic impurities.
[0047] Furthermore, in the mass spectrometry detection, the nebulizer gas was set to 55 psi, the heating auxiliary gas was set to 55 psi, the curtain gas was set to 35 psi, the collision gas was set to 9 psi, the spray voltage was set to 5500 V, the inlet voltage was set to 10 V, the collision chamber outlet voltage was set to 6 V, the ion source temperature was set to 550° C., the dwell time was set to 100 msce, Resolution Q1: Unit, and Resolution Q3: Unit.
[0048] Preferably, the mass spectrometry parameters are set as follows: nebulizer gas is 55psi, heating auxiliary gas is 55psi, curtain gas is 35psi, collision gas is 9psi, spray voltage is 5500V, inlet voltage is 10V, collision chamber outlet voltage is 6V, ion source temperature is 550℃, dwell time is 100msce, Resolution Q1: Unit, Resolution Q3: Unit.
[0049] Further, a mass-to-charge ratio of 383.0→276.1 is used as the impurity Z 1b The detection ion pair is as follows: the mass-to-charge ratio of 309.0→220.1 is used as the impurity Z 1f and its double bond isomer detection ion pair; using a mass-to-charge ratio of 295.0→278.1 as the impurity Z 2a The detection ion pair is as follows: the mass-to-charge ratio 229.0→171.0 is used as the impurity Z 2b The detection ion pair is 383.0→171.0 as the impurity Z2c The detection ion pair is as follows; the mass-to-charge ratio 287.0→229.1 is used as the impurity Z 2d The detection ion pair is as follows: the mass-to-charge ratio of 309.0→278.0 is used as the impurity Z 2e Detection ion pairs.
[0050] Furthermore, the impurity Z with a retention time of 12.68 ± 0.5 min 1b The impurity Z has a retention time of 11.56±0.5min. 1f and its double bond isomers, the retention time is 9.10±0.5min is impurity Z 2a The impurity Z has a retention time of 7.66±0.5min. 2b The impurity Z has a retention time of 8.78±0.5min. 2c The impurity Z has a retention time of 7.92±0.5min. 2d The impurity Z has a retention time of 9.87±0.5min. 2e .
[0051] Based on the above retention time, the impurities can be qualitatively identified.
[0052] The third object of the present invention is to provide a method for determining whether the content of genotoxic impurities in Ibrutinib Z3 is qualified.
[0053] To achieve the above object, the present invention adopts the following technical solutions:
[0054] The method for determining whether the content of genotoxic impurities in Ibrutinib Z3 is qualified comprises the following steps:
[0055] (1) Prepare sample solution and reference solution;
[0056] (2) using the aforementioned identification method to detect the sample solution and the reference solution obtained in step (1) to obtain a chromatogram;
[0057] (3) Establishing a chromatographic model based on the peak area according to the chromatogram of the impurity reference substance;
[0058] (4) Based on the chromatographic model, determine whether the genotoxic impurity content in the sample solution is qualified.
[0059] Preferably, in step (1), the diluent comprises N,N-dimethylacetamide and acetonitrile.
[0060] Preferably, the concentration of the sample solution is 1 mg / ml.
[0061] Preferably, the concentration of the reference solution is 23.5 ng / ml.
[0062] As a preferred technical solution, the method comprises the following steps:
[0063] 1. Take 50 mg of the sample to be tested, weigh it accurately, put it in a 50 ml volumetric flask, add 4 ml of N, N-dimethylacetamide to dissolve it, then dilute it to the scale with 50% acetonitrile, shake well, and use it as the sample solution;
[0064] 2. Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e An appropriate amount of reference substance is accurately weighed, dissolved in N, N-dimethylacetamide and diluted with acetonitrile to make a solution containing about 2.35 μg per 1 ml. Take 0.5 ml of the solution and place it in a 50 ml volumetric flask, first add 4 ml of N, N-dimethylacetamide, then dilute to the mark with 50% acetonitrile, shake well, and use it as the reference substance solution;
[0065] 3. Take the sample solution prepared in step 1 and the reference solution prepared in step 2, inject them separately, detect them according to the above-mentioned chromatographic conditions, and obtain a chromatogram; use the limit method to determine the genotoxic impurities in ibrutinib Z3.
[0066] Furthermore, after the sample solution and the reference solution are prepared, they are placed for no more than 6 hours.
[0067] Furthermore, if the peak areas of the genotoxic impurities contained in the sample solution are not greater than the peak areas of the corresponding impurities in the reference solution, it indicates that the impurity content is qualified; conversely, if the peak area of any genotoxic impurity in the sample solution is greater than the peak area of the corresponding impurity in the reference solution, it indicates that the impurity content is unqualified.
[0068] The beneficial effects of the present invention are:
[0069] 1. The detection method of the present invention can detect the impurity Z in Ibrutinib Z3 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The separation and detection have strong specificity, high sensitivity, high accuracy and good reproducibility, which is of great significance for achieving quality control of ibrutinib Z3.
[0070] 2. The method of the present invention can simultaneously separate the impurity Z in Ibrutinib Z3 in a set of detection systems. 1b 、Impurity Z 1fIts double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e , and the separation time is as low as 25 minutes, which has the advantages of good separation and short separation time.
[0071] 3. The present invention adjusts the LC-MS / MS gradient elution procedure to ensure that impurity Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e They can be well separated and do not interfere with each other in detection; and ibrutinib Z3 and other impurities and matrix do not interfere with the determination of the 7 impurities.
[0072] 4. The method of the present invention meets the limit requirement (23.5 ppm) of ibrutinib Z3 and its seven genotoxic impurities, and 0.94 ng / ml (0.94 ppm) of impurities can be effectively detected, with a low detection limit and high sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS
[0073] Figure 1 The blank solvent contains impurity Z 1b Channel diagram;
[0074] Figure 2 The blank solvent contains impurity Z 1f A diagram of the channel;
[0075] Figure 3 The blank solvent contains impurity Z 2a A diagram of the channel;
[0076] Figure 4 The blank solvent contains impurity Z 2b Channel diagram;
[0077] Figure 5 The blank solvent contains impurity Z 2c A diagram of the channel;
[0078] Figure 6 The blank solvent contains impurity Z 2d A diagram of the channel;
[0079] Figure 7 The blank solvent contains impurity Z 2e A diagram of the channel;
[0080] Figure 8 The detection limit is impurity Z 1b A diagram of the channel;
[0081] Fig. 9 The detection limit is impurity Z 1f A diagram of the channel;
[0082] Fig.10 The detection limit is impurity Z 2a A diagram of the channel;
[0083] Fig.11 The detection limit is impurity Z 2b A diagram of the channel;
[0084] Fig.12 The detection limit is impurity Z 2c A diagram of the channel;
[0085] Fig.13 The detection limit is impurity Z 2d A diagram of the channel;
[0086] Fig.14 The detection limit is impurity Z 2e A diagram of the channel;
[0087] Fig.15 The spiked test solution contains impurity Z 1b A diagram of the channel;
[0088] Fig.16 The spiked test solution contains impurity Z 1f A diagram of the channel;
[0089] Fig.17 For the spiked test solution in impurity Z2 a A diagram of the channel;
[0090] Fig.18 The spiked test solution contains impurity Z 2b A diagram of the channel;
[0091] Fig.19 For the spiked test solution in the presence of impurity Z 2c A diagram of the channel;
[0092] Fig. 20 The spiked test solution contains impurity Z 2d A diagram of the channel;
[0093] Fig.21 The spiked test solution contains impurity Z 2e Channel diagram. DETAILED DESCRIPTION
[0094] The technical solution of the present invention will be further described clearly and completely in conjunction with specific embodiments below. Obviously, the described embodiments are only part of the embodiments of the present invention, rather than all the embodiments. Therefore, based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work belong to the protection scope of the present invention.
[0095] In the present invention, the sample solution is a solution whose main component is ibrutinib Z3, and the sample solution contains impurities Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d 、Impurity Z 2e In addition, the sample solution may also contain other unspecified compounds, which refer to other impurities that may be introduced when preparing Ibrutinib Z3 using conventional methods known in the art.
[0096] Unless otherwise specified, all numerical values and similar values used in the present invention to express parameters are understood to be modified by the term "about". That is, these numerical values are allowed to have certain reasonable deviations or error ranges in practical applications, and do not have to strictly conform to the exact numerical values given. Unless otherwise indicated, the numerical parameters described in the present invention are approximate values that can be changed according to the performance required to be obtained.
[0097] Unless otherwise stated, terms or phrases involved in the present invention should not be considered as uncertain or unclear if there is no special definition, but should be understood according to the ordinary meaning in the art.
[0098] In the present invention, the term "LC-MS / MS", i.e. liquid chromatography-tandem mass spectrometry, is an analytical chemistry technique that combines the separation ability of liquid chromatography and the analytical ability of mass spectrometry. In liquid chromatography-tandem mass spectrometry, liquid chromatography is responsible for separating the analyte from the interfering substance, and mass spectrometry is responsible for detection. After sample injection, the sample first enters the chromatographic column under the carrying of the mobile phase, and after separation by the chromatographic column, enters the mass spectrometry for detection. The mass spectrometry is detected according to the mass-to-charge ratio of the analyte, and the analyte is converted into gaseous ions in the ion source and enters the mass spectrometry. In the triple quadrupole, the primary mass spectrometry scan allows specific ions to enter the collision chamber, and the molecular ions collide and decompose in the collision chamber to form daughter ions to enter the secondary mass spectrometry, and the secondary mass spectrometry scan allows specific fragment ions to enter the detector. LC-MS / MS technology is widely used in many fields such as bioanalysis, drug development, environmental science, and food safety because of its high sensitivity and high selectivity.
[0099] In the present invention, specificity, also known as selectivity or specificity, refers to the ability of the analytical method to accurately and selectively detect the component being measured when other components may be present in the sample. Specificity is a measure of mutual interference when the method is used for complex sample analysis. The present invention verifies whether the HPLC method has sufficient specificity to ensure accurate and unerring determination of the target analyte in complex samples.
[0100] In the present invention, the limit of detection (LOD) refers to the minimum concentration or amount of the target compound that the analytical method can reliably detect. The detection sensitivity of the HPLC method is determined, that is, the lowest concentration of the target analyte in the sample that can be identified. This helps to evaluate the reliability of the method at very low concentrations.
[0101] In the examples of the present invention, information on the compounds involved is shown in Table 1.
[0102] Table 1. Compound information
[0103]
[0104] In the embodiments of the present invention, the main instruments and equipment and experimental parameters are shown in Tables 2 to 4.
[0105] Table 2. Summary of instruments and experimental parameters
[0106]
[0107]
[0108] Table 3. Gradient elution schedule
[0109] Time (min) Mobile phase A Mobile phase B 0 65 35 5 65 35 10 20 80 15 20 80 15.1 65 35 25 65 35
[0110] Table 4. Mass-to-charge ratio information table
[0111] Target to be measured Precursor ion Product ions DP CE <![CDATA[Impurity Z 1b > 383.0 276.1 109 46 <![CDATA[Impurity Z 1f and its double bond isomers]]> 309.0 220.1 90 35 <![CDATA[Impurity Z 2a > 295.0 278.1 81 30 <![CDATA[Impurity Z 2b > 229.0 171.0 60 23 <![CDATA[Impurity Z 2c > 383.0 171.0 140 43 <![CDATA[Impurity Z 2d > 287.0 229.1 60 24 <![CDATA[Impurity Z 2e > 309.0 278.0 80 30
[0112] In the embodiments of the present invention, the determination was carried out strictly in accordance with the high performance liquid chromatography-mass spectrometry method (General Rules 0512 and General Rules 0431 of Part IV of the Chinese Pharmacopoeia 2020 Edition).
[0113] Example 1. Separation and detection of seven genotoxic impurities in ibrutinib intermediate Z3 by LC-MS / MS
[0114] (1) Prepare the test solution
[0115] Test solution: Take 50 mg of the test sample (Ibrutinib Z3), accurately weigh it, put it in a 50 ml volumetric flask, add 4 ml of N, N-dimethylacetamide to dissolve it, then dilute it to the scale with 50% acetonitrile, shake well, and use within 6 hours.
[0116] Reference solution: Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e Take an appropriate amount of reference substance, accurately weigh it, dissolve it in N,N-dimethylacetamide and dilute it with acetonitrile to make a solution containing about 2.35μg per 1ml. Take 0.5ml of the solution and place it in a 50ml volumetric flask, first add 4ml of N,N-dimethylacetamide, then dilute to the scale with 50% acetonitrile, shake well, and use within 6 hours.
[0117] (2) Chromatographic conditions
[0118] Use octadecyl bonded silica gel as filler (Shim-Pack VP-ODS 4.6mm×250mm, 5μm, or chromatographic column with equivalent performance); use 0.2% formic acid water as mobile phase A, acetonitrile as mobile phase B, and perform gradient elution according to Table 3; flow rate is 1ml per minute; column temperature is 30℃; injector temperature control: 6℃; injection volume is 50μl.
[0119] (3) Mass spectrometry conditions
[0120] A tandem quadrupole mass spectrometer was used with an electrospray ionization source (ESI) in positive ion mode with multiple reaction monitoring (MRM). The mass-to-charge ratio (m / z) information is shown in Table 4.
[0121] (4) Determination
[0122] System suitability requirements: Select appropriate mass spectrometry conditions. In the chromatogram of the reference solution, the signal-to-noise ratio of the impurity peak should be no less than 20.
[0123] Determination method: Take the test solution and the reference solution and inject them directly, and record the chromatogram.
[0124] Limit: Impurity Z in the test solution 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The peak area should not be greater than the impurity Z in the reference solution. 1b 、Impurity Z1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e Peak area (0.00235%).
[0125] Example 2. Specificity
[0126] (1) Prepare the test solution
[0127] Blank solvent: a mixed solution of N,N-dimethylacetamide and 50% acetonitrile, wherein the volume ratio of N,N-dimethylacetamide to 50% acetonitrile is 4:50.
[0128] Reference substance stock solution: Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e 23.5 mg of each reference substance is accurately weighed and placed in a 50 ml volumetric flask. After adding appropriate amount of N, N-dimethylacetamide to dissolve, it is diluted to the scale with acetonitrile and shaken to obtain reference substance stock solution I. Accurately transfer 0.5 ml of reference substance stock solution I to a 100 ml volumetric flask, add acetonitrile to dilute to the scale, shaken to obtain reference substance stock solution II.
[0129] Reference substance solution: Accurately pipette 0.5 ml of reference substance reserve solution II into a 50 ml volumetric flask, add 4 ml of N,N-dimethylacetamide, and then dilute to the scale with 50% acetonitrile, shake well, and the solution is ready.
[0130] Test solution: Take about 50 mg of the test sample, accurately weigh it, put it in a 50 ml volumetric flask, add 4 ml of N, N-dimethylacetamide to dissolve it, then dilute it to the scale with 50% acetonitrile, shake well, and you have it.
[0131] (2) Detection
[0132] Take blank solvent, reference solution and test solution, inject them into LC-MS / MS system respectively, and record the chromatogram.
[0133] Results: Figure 1 to Figure 7 As shown, blank solvent and sample matrix did not interfere with the determination of impurities.
[0134] Example 3. System Applicability
[0135] Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e 23.5 mg of each reference substance is accurately weighed and placed in a 50 ml volumetric flask. After adding appropriate amount of N, N-dimethylacetamide to dissolve, it is diluted to the scale with acetonitrile and shaken to obtain reference substance stock solution I. Accurately transfer 0.5 ml of reference substance stock solution I to a 100 ml volumetric flask, add acetonitrile to dilute to the scale, shaken to obtain reference substance stock solution II.
[0136] Accurately pipette 0.5 ml of reference stock solution II into a 50 ml volumetric flask, add 4 ml of N, N-dimethylacetamide, and then dilute to the scale with 50% acetonitrile. Shake well to obtain a mixed solution of about 23.5 ng / ml as the system suitability solution. Accurately measure 50 μl of the solution, inject 6 times continuously, record the chromatogram, and calculate the RSD of the peak area.
[0137] The results are shown in Table 5. 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The RSDs of the impurity peak areas were 3.3%, 1.6%, 0.7%, 1.3%, 0.8%, 0.9% and 0.6%, respectively, and RSD≤15.0%, which was qualified.
[0138] Table 5. System suitability test results
[0139]
[0140]
[0141] Example 4. Detection Limit
[0142] Accurately measure 2 ml of system suitability solution and place it in a 50 ml volumetric flask. Add 4 ml of N, N-dimethylacetamide and dilute to the scale with 50% acetonitrile. Shake well to obtain the detection limit solution. Accurately measure 50 μl of the solution and inject it three times in parallel. Record the chromatogram.
[0143] Results: As shown in Table 6, Figure 8 to Figure 14 As shown, impurity Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2eThe detection limit concentrations were 0.907ng / ml, 0.910ng / ml, 0.919ng / ml, 0.919ng / ml, 0.917ng / ml, 0.865ng / ml and 0.934ng / ml, respectively, equivalent to 0.907ppm, 0.910ppm, 0.919ppm, 0.919ppm, 0.917ppm, 0.865ppm and 0.934ppm.
[0144] Table 6. Results of detection limit test
[0145]
[0146] Example 5. Standard addition test
[0147] (1) Prepare the test solution
[0148] Reference stock solution: Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e 23.5 mg of each reference substance is accurately weighed and placed in a 50 ml volumetric flask. After adding appropriate amount of N, N-dimethylacetamide to dissolve, it is diluted to the scale with acetonitrile and shaken to obtain reference substance stock solution I. Accurately transfer 0.5 ml of reference substance stock solution I to a 100 ml volumetric flask, add acetonitrile to dilute to the scale, shaken to obtain reference substance stock solution II.
[0149] Reference substance solution: Accurately pipette 0.5 ml of reference substance reserve solution II into a 50 ml volumetric flask, add 4 ml of N,N-dimethylacetamide, and then dilute to the scale with 50% acetonitrile, shake well, and the solution is ready.
[0150] Test solution: Take about 50 mg of the test sample, accurately weigh it, put it in a 50 ml volumetric flask, add 4 ml of N, N-dimethylacetamide to dissolve it, then dilute it to the scale with 50% acetonitrile, shake well, and you have it.
[0151] Standard addition solution: Take about 50 mg of the test sample, weigh it accurately, put it in a 50 ml volumetric flask, add 0.5 ml of reference substance stock solution II, add 4 ml of N, N-dimethylacetamide to dissolve it, then add 50% acetonitrile to the scale, shake well, and the standard addition solution is obtained.
[0152] (2) Detection
[0153] The reference solution, test solution and spiked solution were injected, and each sample was measured twice in parallel to calculate the recovery.
[0154] The results are shown in Table 7. Figure 15 to Figure 21 As shown, impurity Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The recoveries of standard addition experiments were 103.0%, 109.6%, 99.2%, 98.2%, 100.7%, 102.3% and 103.0%, respectively. The sample matrix had no significant effect on impurity Z. 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The determination has no effect.
[0155] Table 7. Test results of standard addition test
[0156]
[0157] Example 6. Solution stability
[0158] (1) Prepare the test solution
[0159] Reference stock solution: Take impurity Z 1b 、Impurity Z 1f 、Impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e 23.5 mg of each reference substance is accurately weighed and placed in a 50 ml volumetric flask. After adding appropriate amount of N, N-dimethylacetamide to dissolve, it is diluted to the scale with acetonitrile and shaken to obtain reference substance stock solution I. Accurately transfer 0.5 ml of reference substance stock solution I to a 100 ml volumetric flask, add acetonitrile to dilute to the scale, shaken to obtain reference substance stock solution II.
[0160] Reference substance solution: Accurately pipette 0.5 ml of reference substance reserve solution II into a 50 ml volumetric flask, add 4 ml of N,N-dimethylacetamide, and then dilute to the scale with 50% acetonitrile, shake well, and the solution is ready.
[0161] Standard addition solution: Take about 50 mg of the test sample, weigh it accurately, put it in a 50 ml volumetric flask, add 0.5 ml of reference substance stock solution II, add 4 ml of N, N-dimethylacetamide to dissolve it, then add 50% acetonitrile to the scale, shake well, and the standard addition solution is obtained.
[0162] (2) Detection
[0163] Take the standard added solution and the reference solution, record the chromatograms at 0h, 4h, 6h, and 10h, and calculate the peak area RSD.
[0164] The results are shown in Table 8. 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d and impurity Z 2e The reference solution and the standard addition solution were stable after being placed at 6°C for 10 hours. 1b and impurity Z 1f The reference solution and the standard spiked solution were unstable when placed at 6°C for 10 hours, but stable when placed at 6 hours.
[0165] Table 8. Test results of solution stability test
[0166]
Claims
1. A method for separating ibrutinib Z3 and its genotoxic impurities, characterized in that: The method comprises the following steps: using LC-MS / MS to separate ibrutinib Z3 and its genotoxic impurities; the chromatographic column of the LC-MS / MS method uses octadecyl bonded silica gel as a filler, and the mobile phase includes a mobile phase A and a mobile phase B, wherein the mobile phase A is a formic acid aqueous solution, and the mobile phase B is an organic solvent; and separating ibrutinib Z3 and its genotoxic impurities by gradient elution; The genotoxic impurities include impurity Z 1b 、Impurity Z 1f Its double bond isomers and impurity Z 2a 、Impurity Z 2b 、Impurity Z 2c 、Impurity Z 2d 、Impurity Z 2e Any one or more of; the structural formula of Ibrutinib Z3 is as shown in Formula I, the impurity Z 1b The structural formula is shown in Formula II, and the impurity Z 1f The structural formula is shown in Formula III, and the impurity Z 2a The structural formula is shown in Formula IV, and the impurity Z 2b The structural formula of is shown in Formula V, the impurity Z 2c The structural formula of is shown in Formula VI, the impurity Z 2d The structural formula of is shown in Formula VII, the impurity Z 2e The structural formula is shown in Formula VIII; 2. The method according to claim 1, characterized in that The concentration of the formic acid aqueous solution is 0.1% to 0.3%, and the organic solvent is acetonitrile.
3. The method according to claim 1, characterized in that The following elution program was used for gradient elution: 0min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25; 5min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25; 10 min, the volume ratio of the mobile phase A to the mobile phase B is 10-30:90-70; 15min, the volume ratio of the mobile phase A to the mobile phase B is 10-30:90-70; 15.1min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25; 25min, the volume ratio of the mobile phase A to the mobile phase B is 55-75:45-25.
4. The method according to claim 1, characterized in that Set the flow rate to 1.0±0.2ml / min, the column temperature to 30±2℃; the injector temperature is controlled at 6±1℃.
5. A method for identifying Ibrutinib Z3 and its genotoxic impurities, characterized in that: The steps include: (1) separating ibrutinib Z3 and its genotoxic impurities using the method described in any one of claims 1 to 4; (2) using a tandem quadrupole mass spectrometer to detect and obtain a chromatogram; the detection mode is multiple reaction detection in the positive ion mode of an electrospray ion source; (3) Analyze the chromatographic behavior of the test sample and the reference sample to determine whether the test sample contains the genotoxic impurities.
6. The method according to claim 5, characterized in that The mass-to-charge ratio of 383.0→276.1 is used as the impurity Z 1b The detection ion pair is as follows; the mass-to-charge ratio of 309.0→220.1 is used as the impurity Z 1f and its double bond isomer detection ion pair; using a mass-to-charge ratio of 295.0→278.1 as the impurity Z 2a The detection ion pair is as follows: the mass-to-charge ratio 229.0→171.0 is used as the impurity Z 2b The detection ion pair is 383.0→171.0 as the impurity Z 2c The detection ion pair is as follows; the mass-to-charge ratio 287.0→229.1 is used as the impurity Z 2d The detection ion pair is as follows: the mass-to-charge ratio of 309.0→278.0 is used as the impurity Z 2e Detection ion pairs.
7. The method according to claim 5, characterized in that The impurity Z has a retention time of 12.68±0.5min. 1b The impurity Z has a retention time of 11.56±0.5min. 1f and its double bond isomers, the retention time is 9.10±0.5min is impurity Z 2a The impurity Z has a retention time of 7.66±0.5min. 2b The impurity Z has a retention time of 8.78±0.5min. 2c The impurity Z has a retention time of 7.92±0.5min. 2d The impurity Z has a retention time of 9.87±0.5min. 2e .
8. A method for determining whether the content of genotoxic impurities in Ibrutinib Z3 is qualified, characterized in that: The steps include: (1) Prepare sample solution and reference solution; (2) detecting the sample solution and the reference solution obtained in step (1) using the method described in any one of claims 5 to 7 to obtain a chromatogram; (3) Establishing a chromatographic model based on the peak area according to the chromatogram of the impurity reference substance; (4) Based on the chromatographic model, determine whether the genotoxic impurity content in the sample solution is qualified.
9. The method according to claim 8, characterized in that In step (1), the diluent includes N,N-dimethylacetamide and acetonitrile.
10. The method according to claim 8, characterized in that If the peak areas of the genotoxic impurities in the sample solution are not greater than the peak areas of the corresponding impurities in the reference solution, it indicates that the impurity content is qualified; conversely, if the peak area of any genotoxic impurity in the sample solution is greater than the peak area of the corresponding impurity in the reference solution, it indicates that the impurity content is unqualified.
Citation Information
Patent Citations
Ibrutinib and test method of isomer of ibrutinib
CN104407067A
Analysis method for related substances of Ibrutinib and Ibrutinib preparations
CN106153797A
